Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OpGen, Inc.    OPGN

OPGEN, INC.

(OPGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/21/2020 10/22/2020 10/23/2020 10/26/2020 10/27/2020 Date
2.37(c) 2.4(c) 2.47(c) 2.35(c) 2.24(c) Last
324 246 311 635 875 674 376 990 430 236 Volume
-1.25% +1.27% +2.92% -4.86% -4.68% Change
More quotes
Financials (USD)
Sales 2020 4,29 M - -
Net income 2020 -24,7 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,46x
Yield 2020 -
Sales 2021 11,1 M - -
Net income 2021 -24,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,29x
Yield 2021 -
Capitalization 46,3 M 46,3 M -
Capi. / Sales 2020 10,8x
Capi. / Sales 2021 4,17x
Nbr of Employees 39
Free-Float 99,9%
More Financials
Company
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by... 
More about the company
All news about OPGEN, INC.
03:30pOPGEN : Corporate Presentation (PDF)
PU
10/15OPGEN INC : Results of Operations and Financial Condition (form 8-K)
AQ
10/15OPGEN : Provides Business and Pipeline Update and Announces Preliminary Unaudite..
AQ
10/15OpGen Provides Business and Pipeline Update and Announces Preliminary Unaudit..
GL
10/13OPGEN : Issues Formal Response to FDA's Requests for Additional Information and ..
AQ
10/13OpGen Issues Formal Response to FDA's Requests for Additional Information and..
GL
10/06OPGEN : Corporate Presentation (PDF)
PU
10/05OpGen Group Company Ares Genetics Wins Austrian Digitization Award for ares-g..
GL
10/05OPGEN : Ares Genetics Wins Austrian Digitization Award for ares-genetics.cloud
AQ
10/02OPGEN INC : Change in Directors or Principal Officers, Submission of Matters to ..
AQ
09/30OPGEN : Announces Award of German Government Grant Funding to its Subsidiary Cur..
AQ
09/30OpGen Announces Award of German Government Grant Funding to its Subsidiary Cu..
GL
09/28OPGEN : Announces Successful Completion of Study Collaboration with Karolinska I..
AQ
09/28OpGen Announces Successful Completion of Study Collaboration with Karolinska ..
GL
09/18OPGEN : Announces Notice of Annual Meeting Venue Change
AQ
More news
News in other languages on OPGEN, INC.

- No features available -

More news
Chart OPGEN, INC.
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 5,00 $
Last Close Price 2,35 $
Spread / Highest target 113%
Spread / Average Target 113%
Spread / Lowest Target 113%
EPS Revisions
Managers
NameTitle
Oliver Schacht Chief Executive Officer & Director
Bill E. Rhodes Non-Executive Chairman
Johannes Bacher Chief Operating Officer
Timothy C. Dec CFO, Secretary & Chief Accounting Officer
Vadim Sapiro Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
OPGEN, INC.107.96%46
LONZA GROUP AG62.63%47 039
SEAGEN INC.71.39%34 074
IQVIA HOLDINGS INC.4.96%31 092
CELLTRION, INC.32.04%28 087
MODERNA, INC.259.10%27 716